Myelodysplastic Syndromes – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML). BMS / Acceleron’s Reblozyl (luspatercept) for lower-risk adult MDS, Astex Pharmaceuticals’ Inqovi (decitabine and cedazuridine) for higher-risk adult MDS and refractory MDS, Servier’s Tibsovo (ivosidenib) for relapsed or refractory MDS with an IDH1 mutation, and Geron’s Rytelo (imetelstat) for low- to intermediate-1-risk adult MDS are effective treatment options. Other pharmacological approaches to managing the disease (e.g., lenalidomide [BMS’s Revlimid, generics]) are designed to ameliorate symptoms and extend patients’ survival, although there is a significant gap in the treatment of refractory disease. The MDS pipeline is robust and promising, and several projected market entrants are poised to penetrate the lower-risk, intermediate-risk, and higher-risk subpopulations.

Questions answered

• How have the U.S. launches of Reblozyl, Inqovi, Tibsovo, and Rytelo changed MDS treatment in that country? How will the treatment of MDS in Europe change following the expected EMA label expansions of Tibsovo and launch of Rytelo?
• What is the commercial outlook for current and emerging therapies for MDS?
• Which emerging therapies are most likely to have an impact on the MDS therapy market by 2034?
• How will the size of the MDS population change by 2034?

Geography: United States and EU5

Primary research:

• Country-specific interviews with thought-leading hematologists / oncologists
• Survey data collected for this and other Clarivate research

Epidemiology: Diagnosed incident and diagnosed prevalent cases of MDS by country, diagnosed and drug-treated incident cases of MDS, diagnosed incident and prevalent cases of MDS by morphology, and diagnosed incident and prevalent cases by prognostic risk

Forecast: Drug-level sales and patient share of key MDS therapies in 2024 and 2034

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Niche & Rare Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.